GT BIOPHARMA, INC. Deferred Tax Assets, Goodwill and Intangible Assets
GT BIOPHARMA, INC. (GTBP) had Deferred Tax Assets, Goodwill and Intangible Assets of $57.10 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $57.10M.
- 2024-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $32.60M.
- 2023-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $37.22M.
- 2022-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $41.57M.
| Period end | Deferred Tax Assets, Goodwill and Intangible Assets | Deferred Tax Assets, Goodwill and Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $57.10M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $32.60M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $37.22M 10-K · filed 2025-02-21 | |
| 2022-12-31 | $41.57M 10-K · filed 2024-03-26 | |
| 2021-12-31 | $62.05M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $58.50M 10-K · filed 2022-03-28 | $4.00K 10-K · filed 2021-04-16 |
| 2019-12-31 | $4.00K 10-K · filed 2021-04-16 | |
| 2018-12-31 | $5.00K 10-K · filed 2020-03-27 | |
| 2017-12-31 | -$6.00K 10-K · filed 2019-03-29 | |
| 2016-12-31 | -$11.00K 10-K · filed 2018-03-01 | |
| 2015-12-31 | -$13.00K 10-K/A · filed 2018-02-28 | |
| 2014-12-31 | -$15.00K 10-K/A · filed 2018-02-28 | |
| 2013-12-31 | -$7.00K 10-K · filed 2015-03-31 | -$7.01K 10-K · filed 2015-01-08 |
| 2012-12-31 | -$7.71K 10-K · filed 2015-01-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |